← News
Sep 7, 2026 Psychedelics
Resilient's Resubmitted MDMA Drug Now Has a Name — Rysanso
A trademark filing reveals what Resilient Pharmaceuticals (formerly Lykos, before that MAPS PBC) is calling its resubmitted MDMA-PTSD candidate: Rysanso, filed to cover pharmaceutical and psychedelic preparations. We've covered the resubmission itself — this doesn't change where that stands, but a brand name this far ahead of any approval is its own signal: the company is positioning for a market launch, not just another regulatory round. Read into the name what you want — it lands somewhere between "resilience" and "renaissance," which tracks for a drug that's already survived one rejection and a company-wide rename.
Read at Psychedelic Alpha